Acute Ulcerative Colitis
Immunology
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Tillotts PharmaTP05
Clinical Trials (1)
TP05 for the Treatment of Mild to Moderate Active Ulcerative Colitis (UC)
Start: Jul 2013Est. completion: Nov 2016
Phase 3Completed
Related Jobs in Immunology
Regulatory Affairs Manager(Immunology), Korea
AbbVie
Seoul, Seoul
10h ago
Regional Sales Trainer - Rheumatology (Mid Atlantic/Central)
AbbVie
Remote
11h ago
Field Reimbursement Manager - Rheumatology - Seattle, WA (North)
Johnson & Johnson
Seattle, Washington, United States of America
Yesterday
$100K - $175K/yr
Senior Medical Science Liaison, Dermatology - Indianapolis
Johnson & Johnson
Indianapolis, Indiana, United States
Yesterday
$137K - $236K/yr
Senior Area Business Specialist, Immunology - Detroit, MI - Johnson & Johnson Innovative Medicine
Johnson & Johnson
Detroit, Michigan, United States
Yesterday
Senior Clinical Trial Physician, Rheumatology
Bristol Myers Squibb
Princeton - NJ - US
Yesterday
$309K - $374K/yr
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space